公司資料
Adaptive Biotechnologies 股價、新聞與催化劑
- 股票代碼:
- ADPT
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
24.77 USD (+0.12%)
收盤價
最後更新: 2026年8月17日
2.42B USD
市值
股價為何變動
As of Aug 17, 2026, ADPT was little changed and closed at $24.77. No new same-company headline was identified in the current news window.
公司概覽
Adaptive Immune-System Platform
Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics.
Minimal Residual Disease
The company’s commercial MRD business is led by clonoSEQ, a sequencing-based test used to detect and monitor residual disease in blood cancers. Clinical testing and biopharmaceutical drug-development applications make MRD the company’s principal commercial engine.
Immune Medicine
Adaptive also applies its platform to characterize immune responses and identify disease-specific immune signatures. This business supports biopharmaceutical partnerships and longer-term diagnostic and therapeutic opportunities in cancer and autoimmune disease.
未來催化劑
- Adaptive still has a clean platform story in immune-system diagnostics and therapeutics, but the commercial side is where the company has to keep proving itself. The update is less about one binary event and more about whether the core immune products continue to move from scientific capability into routine clinical use.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。